Pfizer vaults into CD47 arena, buying Trillium for $2.3 billionPfizer is the latest big pharma company to take a position on drugs that target CD47 – a Share XPfizer vaults into CD47 arena, buying Trillium for $2.3 billionhttps://pharmaphorum.com/news/pfizer-vaults-into-cd47-arena-buying-trillium-for-2-3-billion/
2nd Macrophage-directed Therapies SummitHarnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Share X2nd Macrophage-directed Therapies Summithttps://pharmaphorum.com/events/2nd-macrophage-directed-therapies-summit/
ALX Oncology cancer drug claims two FDA fast-track reviewsFresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations Share XALX Oncology cancer drug claims two FDA fast-track reviewshttps://pharmaphorum.com/news/alx-oncology-cancer-drug-claims-two-fda-fast-track-reviews/
